Back to top

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform rating on the shares. Relevant for F...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

argenex SE (ARGX)

Forte Biosciences, Inc. (FBRX)

Teva Pharmaceutical Industries Ltd. (TEVA)